PREPOPIK- sodium picosulfate, magnesium oxide, and anhydrous citric acid powder, metered United States - English - NLM (National Library of Medicine)

prepopik- sodium picosulfate, magnesium oxide, and anhydrous citric acid powder, metered

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 16.1 g - prepopik® is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. prepopik is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute) which may result in accumulation of magnesium [see warnings and precautions (5.4)] - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)] - bowel perforation [see warnings and precautions (5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any of the ingredients in prepopik [see adverse reactions (6.2)] risk summary there are no data with prepopik use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in an animal reproduction study, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1

CLENPIQ- sodium picosulfate, magnesium oxide, and anhydrous citric acid liquid United States - English - NLM (National Library of Medicine)

clenpiq- sodium picosulfate, magnesium oxide, and anhydrous citric acid liquid

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 160 ml - clenpiq is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. clenpiq is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute), which may result in accumulation of magnesium [see warnings and precautions (5.3)]. - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)]. - bowel perforation [see warnings and precautions (5.6)]. - toxic colitis or toxic megacolon. - gastric retention. - hypersensitivity to any of the ingredients in clenpiq [see adverse reactions (6.2)]. risk summary there are no data with clenpiq use in pregnant women to determine a drug-associated risk of adverse developmental outcomes. in animal reproduction studies, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1.2 times the recommended human dose based

SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID- sodium picosulfate, magnesium oxide and anhydrous citric acid pow United States - English - NLM (National Library of Medicine)

sodium picosulfate, magnesium oxide and anhydrous citric acid- sodium picosulfate, magnesium oxide and anhydrous citric acid pow

camber pharmaceuticals, inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate, magnesium oxide and anhydrous citric acid for oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. sodium picosulfate, magnesium oxide and anhydrous citric acid for oral solution is contraindicated in the following conditions: • patients with severe renal impairment (creatinine clearance less than 30 ml/minute) which may result in accumulation of magnesium  [see warnings and precautions ( 5.4)] • gastrointestinal obstruction or ileus [see warnings and precautions ( 5.6)] • bowel perforation [see warnings and precautions ( 5.6)] • toxic colitis or toxic megacolon • gastric retention • hypersensitivity to any of the ingredients in sodium picosulfate, magnesium oxide and anhydrous citric acid for oral solution  [see advers

CLENPIQ- sodium picosulfate, magnesium oxide, and anhydrous citric acid liquid United States - English - NLM (National Library of Medicine)

clenpiq- sodium picosulfate, magnesium oxide, and anhydrous citric acid liquid

asm aerosol-service ag - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - clenpiq is indicated for cleansing of the colon as a preparation for colonoscopy in adults. clenpiq is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute), which may result in accumulation of magnesium [see warnings and precautions (5.3)] - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)] - bowel perforation [see warnings and precautions (5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any of the ingredients in clenpiq risk summary there are no data with clenpiq use in pregnant women to determine a drug-associated risk of adverse developmental outcomes. in animal reproduction studies, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1.2 times the recommended human dose based on body surface area during organogenesis. the estimated background risk of major

CLENPIQ- sodium picosulfate, magnesium oxide, and anhydrous citric acid liquid United States - English - NLM (National Library of Medicine)

clenpiq- sodium picosulfate, magnesium oxide, and anhydrous citric acid liquid

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - clenpiq is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. clenpiq is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute), which may result in accumulation of magnesium [see warnings and precautions (5.3)]. - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)]. - bowel perforation [see warnings and precautions (5.6)]. - toxic colitis or toxic megacolon. - gastric retention. - hypersensitivity to any of the ingredients in clenpiq [see adverse reactions (6.2)]. risk summary there are no data with clenpiq use in pregnant women to determine a drug-associated risk of adverse developmental outcomes. in animal reproduction studies, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1.2 times the recommended human dose based

MAGNESIUM OXIDE tablet United States - English - NLM (National Library of Medicine)

magnesium oxide tablet

richmond pharmaceuticals, inc. - magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838) - magnesium oxide 420 mg - relieves: ■ acid indigestion  ■ upset stomach

MAGNESIUM OXIDE- magnesium oxide tablet United States - English - NLM (National Library of Medicine)

magnesium oxide- magnesium oxide tablet

richmond pharmaceuticals, inc. - magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838) - magnesium oxide 420 mg - relieves: ■ acid indigestion  ■ upset stomach

MAGNESIUM OXIDE tablet United States - English - NLM (National Library of Medicine)

magnesium oxide tablet

bryant ranch prepack - magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838) - magnesium oxide 400 mg

ALKA-SELTZER HEARTBURN (anhydrous citric acid, sodium bicarbonate- heat-treated tablet, effervescent United States - English - NLM (National Library of Medicine)

alka-seltzer heartburn (anhydrous citric acid, sodium bicarbonate- heat-treated tablet, effervescent

bayer healthcare llc. - citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37) - anhydrous citric acid 1000 mg - active ingredients (in each tablet)...................................................................................purpose anhydrous citric acid 1000 mg....................................................................................... antacid sodium bicarbonate (heat-treated) 1940 mg ..............................................................antacid for the relief of - heartburn - acid indigestion - upset stomach associated with these symptoms

MAGNESIUM OXIDE tablet United States - English - NLM (National Library of Medicine)

magnesium oxide tablet

par pharmaceuticals - magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838) - magnesium oxide 400 mg - relieves: ■ acid indigestion  ■ upset stomach